Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: preclinical proof of concept
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Microglia significantly contribute to the pathophysiology of Alzheimer's disease but an effective microglia-targeted therapeutic approach is not yet available clinically. The potassium channels Kv1.3 and Kir2.1 play important roles in regulating immune cell functions and have been implicated by in vitro studies in the 'M1-like pro-inflammatory' or 'M2-like anti-inflammatory' state of microglia, respectively. We here found that amyloid-β oligomer-induced expression of Kv1.3 and Kir2.1 in cultured primary microglia. Likewise, ex vivo microglia acutely isolated from the Alzheimer's model 5xFAD mice co-expressed Kv1.3 and Kir2.1 as well as markers traditionally associated with M1 and M2 activation suggesting that amyloid-β oligomer induces a microglial activation state that is more complex than previously thought. Using the orally available, brain penetrant small molecule Kv1.3 blocker PAP-1 as a tool, we showed that pro-inflammatory and neurotoxic microglial responses induced by amyloid-β oligomer required Kv1.3 activity in vitro and in hippocampal slices. Since we further observed that Kv1.3 was highly expressed in microglia of transgenic Alzheimer's mouse models and human Alzheimer's disease brains, we hypothesized that pharmacological Kv1.3 inhibition could mitigate the pathology induced by amyloid-β aggregates. Indeed, treating APP/PS1 transgenic mice with a 5-month oral regimen of PAP-1, starting at 9 months of age, when the animals already manifest cognitive deficits and amyloid pathology, reduced neuroinflammation, decreased cerebral amyloid load, enhanced hippocampal neuronal plasticity, and improved behavioural deficits. The observed decrease in cerebral amyloid deposition was consistent with the in vitro finding that PAP-1 enhanced amyloid-β uptake by microglia. Collectively, these results provide proof-of-concept data to advance Kv1.3 blockers to Alzheimer's disease clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
In the citing paper
“Kv1.3 channel blockade by the small molecule Pap1 was also found to mitigate Aβ deposition and improve neurobehavioral measures in AD mouse models [49].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · cited 2×
“immune system, which acquire stable phenotypes after subtype differentiation or class-switching, cells of the innate immune system such as microglia are highly plastic and typically do not acquire a stable phenotype that can be readily categorized by specific markers or signature genes (Murray et al., 2014; Bohlen et…”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“A gen- erally accepted hypothesis states that activated microglia re- lease cytotoxic substances and pro-inflammatory cytokines that cause neuronal damage and aggravate Alzheimer’s dis- ease pathology (Heneka et al., 2015).”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Several key conclusions can be drawn from our study: (i) soluble AbO, the highly toxic amyloid-b species implicated as one of the principal initiators of Alzheimer’s disease phenotypes (Selkoe and Hardy, 2016), enhances microglial Kv1.”
BackgroundStructural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 2×
“1, another K + channel often expressed in myeloid cells and involved in regulating their function (Kettenmann et al., 2011; Feske et al., 2015), was highly upregulated (Nguyen et al.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“Alzheimer’s mouse model 5xFAD (Oakley et al., 2006), in which AbO is the major toxic amyloid-b species able to”
BackgroundMethodDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Production and administration of amyloid-b oligomer Amyloid-b oligomer (AbO) was prepared following a standard procedure (Lambert et al., 1998) except that the amyloid-b1-42 peptide (Bachem) was diluted with Opti-MEM culture medium instead of the F12 medium originally described, before incubation…”
MethodNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 3×
“…form part of the age-related changes in microglial function, documented by several lines of investigation, such as altered responses to amyloid-b aggregates or downregulation of ‘sensome’ genes (Hickman et al., 2008, 2013; Cameron et al., 2012; Heneka et al., 2013; Johansson et al., 2015).”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“A network-based analysis of whole-genome gene-expression profiling and genotypic data obtained from 1647 Alzheimer’s disease and non-demented brain samples highlighted the immune/ microglia module as the molecular system most strongly associated with the pathophysiology of Alzheimer’s disease (Zhang et al., 2013).”
BackgroundMethodJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“Similar results were obtained using the other Alzheimer’s transgenic model called APP/PS1 (Jankowsky et al., 2004) (Supplementary Fig.”
Result
Cited by
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
“3 is highly expressed in transgenic AD mouse models and AD patients’ brains (Maezawa et al., 2018).”
BackgroundRangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
BackgroundSelf-citationRen, C., Li, D., Zhou, Q., & Hu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119752 · Cited by 225
Cui, W., Sun, C., Ma, Y., Wang, S., Wang, X., & Zhang, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00444 · Cited by 220
NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology
He, X., Yang, W., Zeng, Z., Wei, Y., Gao, J., Zhang, B., Li, L., Liu, L., Wan, Y., Zeng, Q., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0260-y · Cited by 150
How to reprogram microglia toward beneficial functions
Fumagalli, M., Lombardi, M., Gressens, P., & Verderio, C. (2018) · Glia · doi:10.1002/glia.23484 · Cited by 133
Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson’s disease
Sarkar, S., Nguyen, H. M., Malovic, E., Luo, J. D., Langley, M. R., Palanisamy, B. N., Singh, N., Manne, S., Neal, M. P., Gabrielle, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136174 · Cited by 139
Self-citationPlescher, M., Seifert, G., Hansen, J. N., Bedner, P., Steinhäuser, C., & Halle, A. (2018) · Glia · doi:10.1002/glia.23318 · Cited by 100
“…this idea, it has been shown that Kv channel inhibition diminishes cerebral amyloid load and behavioral deficits in an AD mouse model and decreases production of pro-inflammatory cytokines IL1b, TNFa, IL-6 upon stimulation with Ab peptide in vitro (Franciosi et al., 2006; Maezawa et al., 2017).”
BackgroundIon Channels and Receptors as Determinants of Microglial Function
Izquierdo, P., Attwell, D., & Madry, C. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.007 · Cited by 102
Li, J., Shui, X., Sun, R., Wan, L., Zhang, B., Xiao, B., & Luo, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.736310 · Cited by 88
“PAP-1 can reduce pro-inflammatory cytokine expression and neurotoxicity in microglia induced by amyloid β oligomers (Maezawa et al., 2018).”
BackgroundMicroglia Diversity in Healthy and Diseased Brain: Insights from Single-Cell Omics
Ochocka, N., & Kaminska, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063027 · Cited by 89
“Treatment of APP/PS1 transgenic mice with PAP-1 for 5 months, starting at 9 months of age, reduced numbers of CD68+ cells, decreased cerebral amyloid load, restored hippocampal LTP, and improved cognitive deficits [108].”
BackgroundWang, X., Li, G., Guo, J., Zhang, Z., Zhang, S., Zhu, Y.-D., Cheng, J.-W., Yu, L., Ji, Y.-H., & Tao, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01393 · Cited by 80
“3 blocker, could reduce neuroinflammation, decrease cerebral amyloid load, enhance hippocampal neuronal plasticity, and improve behavioral deficits in APP/PS1 transgenic mice (Maezawa et al., 2018).”
BackgroundMicroglia as Therapeutic Target for Radiation-Induced Brain Injury
Liu, Q., Yan, H., Duan, M., Yang, Q., Ren, B., & Tang, F. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158286 · Cited by 88
Ion channels and transporters in microglial function in physiology and brain diseases
Luo, L., Song, S., Ezenwukwa, C. C., Jalali, S., Sun, B., & Sun, D. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104925 · Cited by 85
Shen, Z., Bao, X., & Wang, R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00314 · Cited by 77
Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease
Jin, L., Lucente, J. D., Nguyen, H. M., Singh, V., Singh, L., Chavez, M., Bushong, T., Wulff, H., & Maezawa, I. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.754 · Cited by 72
Self-citationLiu, H., Jin, M., Ji, M., Zhang, W., Liu, A., & Wang, T. (2022) · Aging · doi:10.18632/aging.203989 · Cited by 77
“The ability to control stagespecific switching of M1/M2 phenotypes at appropriate times might therefore provide therapeutic benefits to AD patients [6, 7].”
BackgroundLucente, J. D., Persico, G., Zhou, Z., Jin, L., Ramsey, J. J., Rutkowsky, J. M., Montgomery, C. B., Tomilov, A. A., Kim, K., Giorgio, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05860-z · Cited by 73
“1a, b) after high-frequency stimulation in the CA3 – CA1 pathway, consistent with our previously described learning and memory de fi cits in these mice 26 .”
Self-citationLv, Z., Chen, L., Chen, P., Peng, H., Rong, Y., Hong, W., Zhou, Q., Li, N., Li, B., Paolicelli, R. C., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.003 · Cited by 69
Zhou, B., Chen, Q., Zhang, Q., Tian, W., Chen, T., & Liu, Z. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03863-5 · Cited by 74
“AD is increasing recognized as a neuroinflammatory condition, where the modulation of microglia M1 and M2 phenotypes becomes crucial [101, 102].”
BackgroundDeciphering cellular transcriptional alterations in Alzheimer’s disease brains
Wang, X., Allen, M., Li, S., Quicksall, Z. S., Patel, T. A., Carnwath, T. P., Reddy, J. S., Carrasquillo, M. M., Lincoln, S. J., Nguyen, T. T., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00392-6 · Cited by 68
The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides
Tajti, G., Wai, D. C. C., Panyi, G., & Norton, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114146 · Cited by 64
Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
Dias, D., & Socodato, R. (2025) · Biomedicines · doi:10.3390/biomedicines13020279 · Cited by 69
“For instance, PAP-1 treatment in APP/PS1 transgenic mice decreased neuroinflammation, reduced cerebral amyloid load, enhanced hippocampal neuronal plasticity, and improved behavioral deficits [89].”
Jin, L., Lucente, J. D., Mendiola, U. R., Suthprasertporn, N., Tomilov, A. A., Cortopassi, G. A., Kim, K., Ramsey, J. J., & Maezawa, I. (2023) · The FASEB Journal · doi:10.1096/fj.202301254r · Cited by 59
“16,17 A β aggregates are recognized by a range of microglial pattern recognition receptors to induce mainly proinflammatory responses that could mediate A β -induced neurotoxicity, impair phagocytic function, and prime microglia to enhance their sensitivity and reactivity to inflammatory stimuli.”
BackgroundSelf-citationMitochondrial K+ channels and their implications for disease mechanisms
Checchetto, V., Leanza, L., Stefani, D. D., Rizzuto, R., Gulbins, E., & Szabó, I. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107874 · Cited by 59
Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges
Gubič, Š., Hendrickx, L. A., Toplak, Ž., Sterle, M., Peigneur, S., Tomašič, T., Pardo, L. A., Tytgat, J., Zega, A., & Mašič, L. P. (2021) · Medicinal Research Reviews · doi:10.1002/med.21800 · Cited by 61
“PAP‐1 improved previously manifested Alzheimer's disease symptoms in trangenic mice with cognitive deficiency and amyloid plaques, and, in in vitro studies, PAP‐1 application promoted higher amyloid‐β uptake by microglia.(181) Studies with diseased mice and rats have documented that PAP‐1 can successfully alleviate sy…”
BackgroundNguyen, H. M., di Lucente, J., Chen, Y., Cui, Y., Ibrahim, R. H., Pennington, M. W., Jin, L., Maezawa, I., & Wulff, H. (2020) · Glia · doi:10.1002/glia.23847 · Cited by 54
“3 expression is upregulated in microglia from intracerebroventricular (ICV)-LPS injected brains (Di Lucente, Nguyen, Wulff, Jin, & Maezawa, 2018).”
BackgroundSelf-citationRamesha, S., Rayaprolu, S., Bowen, C. A., Giver, C. R., Bitarafan, S., Nguyen, H. M., Gao, T., Chen, M. J., Nwabueze, N. V., Dammer, E. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013545118 · Cited by 52
Self-citationVoltage-gated potassium channel 1.3: A promising molecular target in multiple disease therapy
Cheng, S., Jiang, D., Lan, X., Liu, K., & Fan, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116651 · Cited by 45
Chen, X., Feng, Y., Quinn, R. J., Pountney, D. L., Richardson, D. R., Mellick, G. D., & Ma, L. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000743 · Cited by 45
“Indeed, it has been shown to be able to reduce neuroinflammation and neurodegeneration in both PD and Alzheimer’s disease animal models and improve cognition or neurologic deficits in Alzheimer’s disease (Maezawa et al., 2018; Sarkar et al., 2020).”
BackgroundVilla, C., Suphesiz, H., Combi, R., & Akyüz, E. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111197 · Cited by 42
Lai, I. K., Valdearcos, M., Morioka, K., Saxena, S., Feng, X., Li, R., Uchida, Y., An, L., Li, W., Pan, J. Z., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.05.018 · Cited by 38
“Similarly, PAP-1 treatment reduced neuroinflammation, decreased cerebral amyloid load, enhanced hippocampal neuronal plasticity, and improved behavioural deficits in mouse models of Alzheimer’s disease.(40) Kv1.”
BackgroundSelf-citationMicroglia in Alzheimer's Disease: A Role for Ion Channels
Thei, L., Imm, J., Kaisis, E., Dallas, M. L., & Kerrigan, T. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00676 · Cited by 36
“3 at transcript and as protein levels (Maezawa et al., 2017).”
BackgroundKv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling
Fomina, A. F., Nguyen, H. M., & Wulff, H. (2020) · Channels · doi:10.1080/19336950.2020.1853943 · Cited by 42
“3 currents can be recorded from microglia in acute slices [30,31] and from acutely isolated microglia from the brains of 5xFAD mice [7] or from the infarcted area after middle cerebral artery occlusion [5,12], a model for ischemic stroke.”
BackgroundMethodResultSelf-citationLiu, H., Yang, X., Yang, J., Yuan, Y., Wang, Y., Zhang, R., Xiong, H., & Xu, Y. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.679413 · Cited by 35
“According to the previous publication, PAP distributes in parallel in plasma and brain following enteral administration and showed even higher concentration in most tested brain regions than in plasma (Maezawa et al., 2018).”
BackgroundBlockade of Kv1.3 Potassium Channel Inhibits Microglia-Mediated Neuroinflammation in Epilepsy
Zhang, X., Liang, P., Zhang, Y., Wu, Y., Song, Y., Wang, X., Chen, T.-X., Peng, B., Liu, W., Yin, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314693 · Cited by 35
Takahashi, K., Kurokawa, K., Hong, L., Miyagawa, K., Mochida-Saito, A., Takeda, H., & Tsuji, M. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114671 · Cited by 32
Li, X.-T. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00921-w · Cited by 30
Fighting rheumatoid arthritis: Kv1.3 as a therapeutic target
Serrano-Albarrás, A., Cirera-Rocosa, S., Sastre, D., Estadella, I., & Felipe, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.016 · Cited by 29
Roles of Microglial Ion Channel in Neurodegenerative Diseases
Cojocaru, A., Burada, E., Bălșeanu, A.-T., Deftu, A., Cătălin, B., Popa‐Wagner, A., & Osiac, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061239 · Cited by 32
“3 after exposure to a small amount of soluble Aβ [45].”
BackgroundMicroglial ion channels: Key players in non-cell autonomous neurodegeneration
Sarkar, S. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105861 · Cited by 29
Vay, S. U., Flitsch, L. J., Rabenstein, M., Monière, H., Jakovčevski, I., Anđjus, P. R., Bijelić, D. D., Blaschke, S. J., Walter, H. L., Fink, G. R., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01779-4 · Cited by 31
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
“112 Further studies are required to dissect the exact molecular mechanism of this effect, and to assess if diclofenac has a comparable impact on AD pathology via Kv1.”
BackgroundJin, L., Lucente, J. D., Mendiola, U. R., Tang, X., Zivkovic, A. M., Lebrilla, C. B., & Maezawa, I. (2023) · Glia · doi:10.1002/glia.24345 · Cited by 29
“from Aβ42 peptide provides far stronger stimulation to induce microglial activation (Maezawa et al., 2011; Maezawa et al., 2017).”
BackgroundSelf-citationKv1.3 in the spotlight for treating immune diseases
Navarro‐Pérez, M., Capera, J., Benavente-Garcia, A., Cassinelli, S., Colomer-Molera, M., & Felipe, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2315021 · Cited by 27
“Moreover, oral administration has shown to alleviate neuroinflammation, decrease amyloid deposits, enhance hippocampal plasticity, and improve behavioral deficits [97].”
BackgroundChandy, K. G., Sanches, K., & Norton, R. S. (2023) · Channels · doi:10.1080/19336950.2023.2253104 · Cited by 28
“[40] Maezawa I, Nguyen HM, Di Lucente J, et al.”
BackgroundTherapeutic role of voltage-gated potassium channels in age-related neurodegenerative diseases
Urrutia, J., Arrizabalaga-Iriondo, A., Sanchez-del-Rey, A., Martínez-Ibargüen, A., Gallego, M., Casis, Ó., & Revuelta, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1406709 · Cited by 25
Revuelta, M., Urrutia, J., Villarroel, Á., & Casis, Ó. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.868842 · Cited by 25
“3 channel blockade (Maezawa et al., 2018; Ramesha et al., 2021).”
BackgroundGao, T., Raza, S. A., Ramesha, S., Nwabueze, N. V., Tomkins, A. J., Cheng, L., Xiao, H., Yepes, M., & Rangaraju, S. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1510-8 · Cited by 25
Self-citationWang, Z., Sang, M., Zhang, Y., Chen, S., Li, S., Chen, Y., Xu, E., Zhou, Q., Xu, W., Zhao, C., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116624 · Cited by 22
The NLRP3 Inflammasome in the Pathogenesis and Treatment of Alzheimer’s Disease
Golzari-Sorkheh, M., Brown, C. E., Weaver, D. F., & Reed, M. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210660 · Cited by 23
“3 channel will have potential for reducing AD pathologies caused by pro-inflammatory and A (cid:2) -induced neurotoxic microglial responses [127].”
InfluentialSex- and Development-Dependent Responses of Rat Microglia to Pro- and Anti-inflammatory Stimulation
Lively, S. S., Wong, R., Lam, D., & Schlichter, L. C. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00433 · Cited by 22
“, 2014), Alzheimer’s symptoms in mouse models (Maezawa et al., 2018), and microglia infiltration into glioblastoma tumors (Grimaldi et al.”
BackgroundKv1.3 K + Channel Physiology Assessed by Genetic and Pharmacological Modulation
Varanita, T., Angi, B., Scattolini, V., & Szabó, I. (2022) · Physiology · doi:10.1152/physiol.00010.2022 · Cited by 24
Role of Ion Channels in Alzheimer’s Disease Pathophysiology
Bhoi, R., Mitra, T., Tejaswi, K., Manoj, V., & Ghatak, S. (2025) · The Journal of Membrane Biology · doi:10.1007/s00232-025-00341-8 · Cited by 19
“…in AD models reduced Aβ levels, increased synaptic proteins and switched microglial gene expression toward protective and phagocytic phenotypes, thereby suggesting a possibility of an immune modulatory target for use in immunomodulation against AD (Maezawa et al. 2018; Ramesha et al., n.d.).”
Parrasia, S., Rossa, A., Varanita, T., Checchetto, V., Lorenzi, R. D., Zoratti, M., Paradisi, C., Ruzza, P., Mattarei, A., Szabó, I., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14020129 · Cited by 19
Nicolazzo, J. A., Pan, Y., Stefano, I. D., Choy, K. H. C., Reddiar, S. B., Low, Y. L., Wai, D. C. C., Norton, R. S., & Jin, L. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.11.003 · Cited by 19
Self-citationMicroglial Potassium Channels: From Homeostasis to Neurodegeneration
Cocozza, G., Garofalo, S., Capitani, R., D’Alessandro, G., & Limatola, C. (2021) · Biomolecules · doi:10.3390/biom11121774 · Cited by 20
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Cacabelos, R., Naidoo, V., Martínez-Iglesias, O. A., Corzo, L., Cacabelos, N., Pego, R., & Carril, J. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_13 · Cited by 19
Liu, X., Wang, H., Tian, X., Luo, Y., Ma, M., Zheng, Z., Wang, Y., Feng, S., Wang, Q., Xu, Z. F., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03488-2 · Cited by 21
The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion
Chen, Y., Cui, Y., Singh, L., & Wulff, H. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51456 · Cited by 18
Self-citationWu, W., An, X., Gong, W., Yang, L., Liu, N., Liu, B., Guo, B., Jiang, Q. Y., & Li, L. (2024) · Advanced Science · doi:10.1002/advs.202406822 · Cited by 27
Xia, F., Ren, J., Liu, L., Cui, Y., & He, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1515094 · Cited by 20
Functional Potassium Channels in Macrophages
Man, Q., Gao, Z., & Chen, K. (2023) · The Journal of Membrane Biology · doi:10.1007/s00232-022-00276-4 · Cited by 15
Goyal, P., Baldaniya, L. H., Tyagi, L. K., Joshi, K. K., Ballal, S., Sabarivani, A., Ray, S., Nathiya, D., Chauhan, A. S., Gulati, M., et al. (2026) · Brain Sciences · doi:10.3390/brainsci16020154 · Cited by 13
Takahashi, K., Tsuji, M., Nakagawasai, O., Katsuyama, S., Miyagawa, K., Kurokawa, K., Mochida-Saito, A., Takeda, H., & Tadano, T. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105723 · Cited by 13
Identification of WP1066, an inhibitor of JAK2 and STAT3, as a KV1.3 potassium channel blocker
Li, M., & Yu, H. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15441 · Cited by 16
“In microglia-mediated neuroinflammatory and neurodegenerative dis- eases, such as multiple sclerosis (Rus et al., 2005), Alzheimer's dis- ease (Maezawa et al., 2018) and Parkinson's disease (Sarkar Abbreviations: CFA, complete Freund's adjuvant; DTH, delayed-type hypersensitivity; hERG, human…”
Chen, Y., Zhi, Y., Zhong, H., Ma, L., Gu, X., Cai, Y., Huang, J., Yi, X., Wu, X., Yung, K. K. L., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107623 · Cited by 12
Pan, Y., Kagawa, Y., Sun, J., Lucas, D. D., Takechi, R., Mamo, J. C. L., Wai, D. C. C., Norton, R. S., Jin, L., & Nicolazzo, J. A. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01387-z · Cited by 12
“3 also enhanced the ability of microglia to phagocytose Aβ in APP/PS1 mice [12], and enhanced the clearance of Aβ from the brain in 5 × FAD mice [14, 15].”
BackgroundInfluentialSelf-citationThe role of ion channels in the relationship between the immune system and cancer
Erdoğan, M. A., Ugo, D., & Fasolino, I. (2023) · Current topics in membranes · doi:10.1016/bs.ctm.2023.09.001 · Cited by 14
Reddiar, S. B., Jin, L., Wai, D. C. C., Csóti, A., Panyi, G., Norton, R. S., & Nicolazzo, J. A. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.03.002 · Cited by 12
Self-citationReddiar, S. B., de Veer, M., Paterson, B. M., Sepehrizadeh, T., Wai, D. C. C., Csóti, A., Panyi, G., Nicolazzo, J. A., & Norton, R. S. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00614 · Cited by 12
Proteomic Investigation of Murine Neuronal α7-Nicotinic Acetylcholine Receptor Interacting Proteins
Mulcahy, M. J., Paulo, J. A., & Hawrot, E. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00618 · Cited by 12
Wang, B., Chen, J., Wang, S., Chen, L., Zhang, X., Zhou, T., Zhong, J., Zhang, C., He, Y., Zuo, Y., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206171 · Cited by 11
Shifting Microglial Phenotypes: Targeting Disease-Associated Microglia in Neurodegeneration
Sasidharan, A., Somayaji, Y., & Fernandes, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00159 · Cited by 11
Rey, F., Messa, L., Maghraby, E., Casili, G., Ottolenghi, S., Barzaghini, B., Raimondi, M. T., Cereda, C., Cuzzocrea, S., Zuccotti, G., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0046 · Cited by 11
Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11
Zhang, X., Lin, X., Luo, H., Zhi, Y., Yi, X., Wu, X., Duan, W.-D., Cao, Y., Pang, J., Liu, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106112 · Cited by 10
Conditional knockout of Tsc1 in RORγt-expressing cells induces brain damage and early death in mice
Deng, Y., Yao, Y., Yang, Y., Li, Y., Peng, H., Wu, S., Zhang, S., Yao, B., Li, S., Gao, Y., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02153-8 · Cited by 11
Sanches, K., Prypoten, V., Chandy, K. G., Chalmers, D. K., & Norton, R. S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01237 · Cited by 11
Takahashi, K., Nakagawasai, O., Kurokawa, K., Miyagawa, K., Mochida-Saito, A., Takeda, H., & Tsuji, M. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10232-3 · Cited by 9
Tang, X., Schindler, R. L., Lucente, J. D., Oloumi, A., Tena, J., Harvey, D. J., Lebrilla, C. B., Zivkovic, A. M., Jin, L., & Maezawa, I. (2025) · Scientific Reports · doi:10.1038/s41598-025-96596-1 · Cited by 11
Self-citationThe impact of mild episodic ketosis on microglia and hippocampal long‐term depression in 5xFAD mice
Lucente, J. D., Ramsey, J. J., Jin, L., & Maezawa, I. (2024) · FASEB BioAdvances · doi:10.1096/fba.2024-00123 · Cited by 8
“We used hippocampal slices to evaluate both hLTP and hLTD at the Schaffer collateral-CA1 synapses, induced by standard high-frequency stimulation 29 and low-frequency stimulation, 30 respectively.”
Self-citationUnraveling neuroprotection with Kv1.3 potassium channel blockade by a scorpion venom peptide
Beraldo-Neto, E., Ferreira, V. F., Vigerelli, H., Beraldo, K. R. F., Juliano, M. A., Nencioni, A. L. A., & Pimenta, D. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-79152-1 · Cited by 8
ShK toxin: history, structure and therapeutic applications for autoimmune diseases
Chang, S. C., Bajaj, S., & Chandy, K. G. (2018) · WikiJournal of Science · doi:10.15347/wjs/2018.003 · Cited by 8
“3 blocker (PAP-1) alleviated Alzheimer’s diseaselike characteristics in a mouse model of AD.([62])”
Backgroundl -Fucose is a candidate monosaccharide neuromodulator and mitigates Alzheimer’s synaptic deficits
Lucente, J. D., Tena, J., Bai, Y., Shafer, C. C., Mendiola, U. R., Neumann, E. K., Chen, X., Lebrilla, C. B., Maezawa, I., & Jin, L. (2025) · Science Advances · doi:10.1126/sciadv.adt4123 · Cited by 7
Self-citationLi, B., Gao, Y. H., Han, H., Wang, Z., Zhang, Y., Li, Y., & Ling, Y. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111351 · Cited by 7
“3 channel with PAP-1 not only suppressed the pro-inflammatory microglial phenotype but also enhanced the anti-inflammatory phenotype, thereby improving β-amyloid clearance and alleviating behavioral deficits [19].”
Wang, Y., & Han, B. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220726163514 · Cited by 7
Ratano, P., Cocozza, G., Pinchera, C., Busdraghi, L. M., Cantando, I., Martinello, K., Scioli, M., Rosito, M., Bezzi, P., Fucile, S., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1333745 · Cited by 5
Self-citationLee, R. D., Chen, Y., Singh, L., Nguyen, H. M., & Wulff, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190476 · Cited by 5
“3 blockers reduce expression of iNOS and COX-2 and production of inflammatory cytokines and NO following stimulation with LPS, amyloid-β, α-synuclein or ischemia/hypoxia (Chen et al., 2018; Maezawa et al., 2018; Sarkar et al., 2020).”
BackgroundSelf-citationMoussaoui, H., Ladjel‐Mendil, A., & Laraba‐Djebari, F. (2022) · Toxin Reviews · doi:10.1080/15569543.2021.2022698 · Cited by 4
Nuance of inward rectifying potassium (Kir) channel dysfunctions in neurodegenerative diseases
Garland, B., & Ma, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385870 · Cited by 4
“1 activation following LPS treatment (Maezawa et al., 2018; Figure 1f ).”
BackgroundKv1.3 In Microglia: Neuroinflammatory Determinant and Promising Pharmaceutical Target
Felipe, A. (2018) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2018/4.1191 · Cited by 4
Shalaby, H. N., Nawwar, D. A., Kamel, A. S. E. D., & El-Said, Y. A. M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177647 · Cited by 3
Tarai, A., Mitra, T., Pain, T., Mallick, J., Chakraborty, R., Tejaswi, K., Ghatak, S., & Kar, S. (2026) · Advanced Science · doi:10.1002/advs.202515462 · Cited by 5
Wu, X., He, T., Yang, C., Xue, S., Yuan, Q., Chen, F., Liu, J., & Li, G. (2025) · International Journal of Hyperthermia · doi:10.1080/02656736.2025.2503312 · Cited by 3
“Our findings suggest that TLR4 may be involved in HS-related neurological injury and that inhibiting TLR4 could reduce neurological damage following HS. Microglia are the resident macrophage cells in the CNS responsible for mediating neuroinflammation, brain development, and injury repair [29,30].”
Cojocaru, A., Rotaru-Zăvăleanu, A. D., Călina, D. C., Gheonea, D. I., Osiac, E., Boboc, I. K. Ş., & Mitran, S. I. (2021) · PubMed Central · doi:10.12865/chsj.47.02.17 · Cited by 3
“However, a large amount of molecular processes that can influence the evolution of AD have been discovered [5,6,23-26].”
BackgroundNon-conducting functions of potassium channels in cancer and neurological disease
Sesti, F., Bortolami, A., & Forzisi, E. (2023) · Current topics in membranes · doi:10.1016/bs.ctm.2023.09.007 · Cited by 3
Liu, H., Jin, M., Ji, M., Zhang, W., Liu, A., & Wang, T. (2021) · Research Square · doi:10.21203/rs.3.rs-445479/v1 · Cited by 3
Wang, Y., Wang, Q., Li, R., Yu, Y., Feng, S., Wu, W., & Ren, S. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107185 · Cited by 2
Kour, D., Srivastava, U., Eddy, T., Mehta, L., Kumari, R., & Rangaraju, S. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102757 · Cited by 2
Self-citation
Metadata
- Authors
- Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., & Jin, L.-W.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, 2805 50th Street, Sacramento, CA 95817, USA
- Emory University (US)
- Corresponding author
- Maezawa, Izumi
- Wulff, Heike
- Jin, Lee-Way
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-18
- Volume
- 141
- Issue
- 2
- Pages
- 596-612
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5837198
- OpenAlex
- W2780797805
- Cited by
- 125
- References
- 78
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 15 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 14 · 2019: 7 · 2018: 9
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Kv1.3 potassium channel, Kir2.1, microglia, Alzheimer's disease, amyloid-beta oligomers, PAP1, microglial activation, macrophage polarization, neuroinflammation, cerebral amyloid deposition, APP/PS1 mice, hippocampal plasticity, microglia-targeted therapy
- MeSH terms
- Alzheimer Disease, Animals, Animals, Newborn, Avoidance Learning, Cells, Cultured, Disease Models, Animal, Exploratory Behavior, Ficusin, Gene Expression Regulation, Membrane Potentials, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Potassium Channel Blockers, Mice, Kv1.3 Potassium Channel, Shab Potassium Channels, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.